7th February 2019
("IXICO" or the "Company")
Appointment of Chief Financial Officer
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, is pleased to announce the appointment of Grant Nash as the Company's Chief Financial Officer. Grant will join the Company on 29th April 2019 and it is anticipated that he will join the board in due course.
Grant joins IXICO from the UK Biobank, a national and international health research data resource, where he has been Finance Director since 2014. Whilst with the UK Biobank, Grant was also responsible for the UK Biocentre, which provides biomedical sample processing and archiving logistics to large-scale research studies. He was involved in separate fundraisings to raise more than £140 million for a variety of research and development projects. Prior to his time with the UK Biobank, Grant spent 10 years with Evotec AG, latterly as Senior Vice President of Finance, where he was responsible for the finance, IT, procurement facilities and logistics functions. Evotec AG is a drug discovery business which reached 600 employees and sales of approximately €100 million during his tenure. Grant qualified as a Chartered Accountant with PwC.
Conor Woolfson who assumed the role of interim Head of Finance in December 2018, will continue to perform these duties prior to Grant's appointment, at which time he will then continue in his role of Group Financial Controller, reporting to Grant.
Giulio Cerroni, Chief Executive of IXICO, said: "I am delighted to welcome Grant to the Company and I look forward to him bringing his financial leadership skills and experience in the sector to IXICO. I would also like to thank Conor Woolfson, who in addition to his responsibilities as Group Financial Controller, stepped into the role of interim Head of Finance in December.
"We are at an exciting stage of the Company's development, and Grant's business experience in international commercial and large-scale research and development organisations will assist the Board and management team in delivering against our strategic objectives."
For further information please contact:
Giulio Cerroni, Chief Executive Officer
Tel: +44 20 3763 7498
| || |
Shore Capital (Nomad and Broker)
Edward Mansfield/Anita Ghanekar/Daniel Bush
Tel: +44 20 7408 4090
| || |
FTI Consulting Limited (Investor Relations)
Tel: +44 20 3727 1000
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel medical imaging and mobile health digital technologies.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.